Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Own stem cells infused in spinal cord injury hope

NCT ID NCT03925649

Disease control Sponsor: Hope Biosciences LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended) This study
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This expanded access program gives one patient with a spinal cord injury at the C5-C7 level a single infusion of their own stem cells (HB-adMSCs). The stem cells are taken from the patient's fat tissue and grown in a lab before being given back. The goal is to see if this approach is safe and might help with recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous adipose-derived mesenchymal stem cells (HB-adMSCs)
What this could lead to
If this works, it could point toward a way to improve function or slow damage after spinal cord injury.
What could go wrong
This is an expanded access program for just one patient, not a full trial. It is too early to know if stem cells help spinal cord injury, and there may be risks like infection or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cognitively intact, capable of giving informed consent * Clinical diagnosis of a non-penetrating traumatic SCI * Asia Impairment Scale grade of A, B, or C Exclusion Criteria: 1. Prior history of: * Brain injury * Recent or ongoing infection * Clinically significant cardiovascular, lung, renal, hepatic or endocrine disease, * Neurodegenerative disorders * Cancer * Immunosuppression as defined by WBC\<3,000 cells/ml at baseline screening, * HIV+ * Chemical or ETOH dependency 2. Having a contraindication to MRI scans 3. Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSC administration 4. Participation in other interventional research studies 5. Unwillingness to return for follow-up visits

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Spinal cord injury at C5-C7 level are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

palsy quadriplegia spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Spinal cord injury at C5-C7 level

Contacts and locations

Locations

  • Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU)

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.